Moderate to Severe Atopic Dermatitis: An Update for Pharmacists

Activity Description

This activity is designed to provide pharmacists with the latest updates in AD pathophysiology and the role of interleukin and JAK as targets in AD treatment. Learners will discuss the latest clinical trial data and current and emerging treatments for AD. A special focus on quality of life challenges along with best practices for counseling and therapeutic management will provide pharmacists with skills to improve outcomes in young adults with moderate-severe AD.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

  • Discuss the underlying pathophysiology of moderate-severe atopic dermatitis, including inflammatory pathways and associated drug targets.
  • Examine the most recent clinical trial data for current and emerging atopic dermatitis treatments, their mechanisms of action, safety, efficacy, and place in therapy.
  • Describe strategies to manage the impact of moderate-to-severe atopic dermatitis on quality of life in young adults.


Steven A. Scott, PharmD
Associate Professor
Purdue University College of Pharmacy
West Lafayette, Indiana

CE Accreditation

Release Date: April 1, 2021
Expiration Date: April 1, 2022


ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-081-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Scott does not have any relevant commercial and/or financial relationships to disclose.


This activity is supported by an educational grant from Incyte Corporation.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.